<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ivabradine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ivabradine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ivabradine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="101166" href="/d/html/101166.html" rel="external">see "Ivabradine: Drug information"</a> and <a class="drug drug_patient" data-topicid="101348" href="/d/html/101348.html" rel="external">see "Ivabradine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F27975706"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Corlanor</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871912"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Lancora</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F53195676"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Cardiovascular Agent, Miscellaneous</span></li></ul></div>
<div class="block dop drugH1Div" id="F53291219"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="44e8acc1-869a-4cc8-aaf4-0590d12bbe9c">Heart failure, dilated cardiomyopathy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart failure, dilated cardiomyopathy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months, Children, and Adolescents &lt;18 years:</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;40 kg: Oral: Initial: 0.05 mg/kg/dose twice daily; may increase dose every 2 weeks by 0.05 mg/kg/dose as tolerated to achieve a 20% reduction in heart rate without inducing bradycardia.</p>
<p style="text-indent:-2em;margin-left:8em;">Maximum dose: Age-dependent:</p>
<p style="text-indent:-2em;margin-left:10em;">≥6 months to &lt;1 year: 0.2 mg/kg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:10em;">≥1 year: 0.3 mg/kg/dose twice daily, not to exceed 7.5 mg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Dosage adjustment for bradycardia:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Initial dose: Decrease dose to 0.02 mg/kg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:10em;">During titration: Decrease dose to previous dose.</p>
<p style="text-indent:-2em;margin-left:6em;">≥40 kg: Oral: Initial: 2.5 mg twice daily; may increase dose every 2 weeks by 2.5 mg as tolerated to achieve a 20% reduction in heart rate without inducing bradycardia; maximum dose: 7.5 mg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Dosage adjustment for bradycardia:</i> Decrease dose to previous dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥18 years: Oral: Initial: 5 mg twice daily or 2.5 mg twice daily in patients with a history of conduction defects or who may experience hemodynamic compromise due to bradycardia; after 2 weeks, adjust dose to achieve a resting heart rate between 50 and 60 beats per minute (bpm); adjust dose as needed based on resting heart rate and tolerability; maximum dose: 7.5 mg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Dosage adjustment based on resting heart rate:</i></p>
<p style="text-indent:-2em;margin-left:8em;">If heart rate &gt;60 bpm: Increase dose by 2.5 mg twice daily; maximum dose: 7.5 mg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">If heart rate 50 to 60 bpm: Maintain dose.</p>
<p style="text-indent:-2em;margin-left:8em;">If heart rate &lt;50 bpm or signs and symptoms of bradycardia: Decrease dose by 2.5 mg twice daily; if current dose is 2.5 mg twice daily, discontinue therapy.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F53291261"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants ≥6 months, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥15 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;15 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F53291262"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants ≥6 months, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: Use is contraindicated (has not been studied; increase in systemic exposure anticipated).</p></div>
<div class="block doa drugH1Div" id="F27857551"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="101166" href="/d/html/101166.html" rel="external">see "Ivabradine: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b43376ec-cceb-40f9-ad1e-9137f312af09">Heart failure with reduced ejection fraction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart failure with reduced ejection fraction (adjunctive agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May be considered for additional therapy in patients who are persistently symptomatic despite an optimal medical regimen for heart failure with reduced ejection fraction. Consider for use in stable, euvolemic patients who are in sinus rhythm with resting heart rate ≥70 beats per minute (bpm) despite being on a target or maximally tolerated dose of beta blocker or if there is a contraindication to beta-blocker use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33446410']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33446410'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 5 mg twice daily <b>or</b> 2.5 mg twice daily in patients with a history of conduction defects or who may experience hemodynamic compromise due to bradycardia. Adjust dose every ≥2 weeks as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33446410','lexi-content-ref-20801500']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33446410','lexi-content-ref-20801500'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dosage adjustment based on resting heart rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33446410','lexi-content-ref-20801500']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33446410','lexi-content-ref-20801500'])">Ref</a></span>)</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">If heart rate &gt;60 bpm: Increase dose by 2.5 mg twice daily; maximum dose: 7.5 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">If heart rate 50 to 60 bpm: Maintain dose.</p>
<p style="text-indent:-2em;margin-left:6em;">If heart rate &lt;50 bpm or signs and symptoms of bradycardia: Decrease dose by 2.5 mg twice daily; if current dose is 2.5 mg twice daily, discontinue therapy.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3382a490-268a-46b6-a4cf-ae0e6508853a">Inappropriate sinus tachycardia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Inappropriate sinus tachycardia (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 5 mg twice daily; maintenance: 7.5 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26409259','lexi-content-ref-22981555']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26409259','lexi-content-ref-22981555'])">Ref</a></span>). May also use in combination with a beta-blocker (eg, metoprolol) in patients who are refractory to monotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23426376']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23426376'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f2b2404a-fe0d-423d-b4de-010442514217">Stable angina</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Stable angina (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Consider for use if symptoms are not controlled on beta-blocker or calcium channel blocker monotherapy. If combined with a calcium channel blocker, use of a dihydropyridine (such as slow-release nifedipine, amlodipine, or felodipine) is suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23996286','lexi-content-ref-NICE.2011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23996286','lexi-content-ref-NICE.2011'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults &lt;75 years of age: <b>Oral:</b> Initial: 2.5 to 5 mg twice daily; titrate up in increments of 2.5 mg after 3 to 4 weeks if symptoms persist and heart rate is &gt;60 bpm; maximum dose: 7.5 mg twice daily. Discontinue therapy if angina symptoms do not improve within 3 months of initiation. Also consider discontinuation if improvement of angina symptoms is limited and no clinically significant heart rate reduction occurs in the first 3 months. If heart rate is &lt;50 bpm at rest or patient experiences symptomatic bradycardia (eg, dizziness, fatigue, hypotension) during therapy, decrease dose by 2.5 mg per dose, or discontinue if already at the minimum dose of 2.5 mg twice daily. Monitor heart rate carefully after dosage reduction. If heart rate continues to be &lt;50 bpm or symptoms of bradycardia persist, discontinue therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Corlentor.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Corlentor.2'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990265"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥15 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;15 mL/minute: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50987462"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild or moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C): Use is contraindicated (has not been studied; increase in systemic exposure anticipated).</p></div>
<div class="block adr drugH1Div" id="F28562238"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (4% to 10%), hypertension (9%), atrial fibrillation (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Phosphene (3%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Cardiovascular: Heart block, sinoatrial arrest</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Angioedema, diplopia, erythema, hypotension, pruritus, skin rash, syncope, torsades de pointes, urticaria, ventricular fibrillation, ventricular tachycardia, vertigo, visual impairment</p></div>
<div class="block coi drugH1Div" id="F27787811"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Acute decompensated heart failure; clinically significant hypotension; sick sinus syndrome, sinoatrial block, or third-degree AV block (unless a functioning demand pacemaker is present); clinically significant bradycardia; severe hepatic impairment; pacemaker dependence (heart rate maintained exclusively by the pacemaker); concomitant use with strong CYP3A4 inhibitors.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling</i>: Additional contraindications (not in US labeling): Hypersensitivity to ivabradine or any component of the formulation; resting heart rate &lt;70 bpm prior to treatment; prolonged QT interval (eg, congenital long QT syndrome); cardiogenic shock; acute myocardial infarction; concomitant use of verapamil or diltiazem; pregnancy, breastfeeding, or women of child-bearing potential not using appropriate contraception; hereditary problems of galactose intolerance, glucose-galactose malabsorption, or the congenital lactase deficiency.</p></div>
<div class="block war drugH1Div" id="F27857538"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse events:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Atrial fibrillation: Use increases the risk of atrial fibrillation; monitor cardiac rhythm. Discontinue if atrial fibrillation develops.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bradycardia and conduction disturbances: Bradycardia, sinus arrest, and heart block may occur; monitor heart rate prior to initiation and with any dosage adjustment. Bradycardia may increase the risk of QT prolongation, which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs. Risk factors for bradycardia include sinus node dysfunction, conduction defects (eg, first- or second-degree AV block, bundle branch block), ventricular dyssynchrony, and use of other negative chronotropes (eg, digoxin, diltiazem, verapamil, amiodarone). Avoid concurrent use with verapamil and diltiazem. Avoid use in patients with second-degree AV block (unless a functioning demand pacemaker is present). Use is contraindicated in patients with sick sinus syndrome, sinoatrial block, third-degree AV block (unless a functioning demand pacemaker is present), or pacemaker dependence. Decrease dose or discontinue use if heart rate &lt;50 bpm persists during therapy or signs and symptoms of bradycardia occur. Use is contraindicated in patients with clinically significant bradycardia. In patients with history of conduction defects or in whom bradycardia could lead to hemodynamic compromise, initial dosage reduction is recommended. Heart rate reduction may prolong the uncorrected QT interval while QTc interval remains unchanged (Camm 2003; Murat 2009). At concentrations slightly higher than that achieved with therapeutic dosing, ivabradine prolonged ventricular repolarization in perfused guinea-pig hearts (Melgari 2015). Torsades de pointes has been reported when used with other drugs that produce bradycardia or prolong the QT interval (Cocco 2015; Mittal 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">• Visual function: Phosphenes (described as transient enhanced brightness in a limited area of the visual field, halos, image decomposition, colored bright lights, or multiple images) may occur with use. Onset is generally within the first 2 months of therapy and is reported to be of mild to moderate intensity; most cases resolve during or after treatment discontinuation.</p></div>
<div class="block foc drugH1Div" id="F27975707"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Corlanor: 5 mg/5 mL (5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Corlanor: 5 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Corlanor: 7.5 mg</p></div>
<div class="block geq drugH1Div" id="F27975705"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F28326124"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Corlanor Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/5 mL (per mL): $2.38</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Corlanor Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $11.92</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5 mg (per each): $11.92</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871913"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lancora: 5 mg, 7.5 mg [contains corn starch]</p></div>
<div class="block accres drugH1Div" id="F54504882"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Corlanor oral solution (for outpatient use) is exclusively distributed through Avella Specialty Pharmacy. Call 1-844-6CORLANOR or visit https://www.corlanorhcp.com/pediatric-indication for additional information.</p></div>
<div class="block admp drugH1Div" id="F53291263"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with food. For oral solution, empty entire contents of ampule(s) into a medication cup; use a calibrated oral syringe to measure prescribed dose from the medication cup. Discard any unused oral solution. Rinse oral syringe and medicine cup with warm, running water after use and air dry.</p>
<p style="text-indent:-2em;margin-left:2em;">If a dose is missed or spit out, do not administer another dose; administer next dose at usual time.</p></div>
<div class="block adm drugH1Div" id="F27857556"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer with food. Oral solution can be used for adults unable to swallow tablets. For oral solution, empty entire contents of ampule(s) into a medication cup; use a calibrated oral syringe to measure prescribed dose from the medication cup. Discard any unused oral solution.</p></div>
<div class="block hazard drugH1Div" id="F51765892"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Ivabradine may cause teratogenicity.</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block sts drugH1Div" id="F27857540"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 25ºC (77ºF); excursions are permitted between 15ºC and 30ºC (59ºF and 86ºF). To protect from light, keep oral solution ampules in original foil pouches until use.</p></div>
<div class="block meg drugH1Div" id="F27788000"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Corlanor: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F206143s007lbl.pdf%23page%3D24&amp;token=GuTOJ9E%2FlACoqWm7FUv1xqVd%2FWNk2Dl8TQLuvKqqKcr%2B%2Fpftg0T4o6ffHP4942rEmGdDgIcwD59rdTeiQyE1Ai2xwpwd8vbDjH%2B6zj44EUk6f31Bz9XLrrOmXegRCfqW&amp;TOPIC_ID=121652" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206143s007lbl.pdf#page=24</a></p></div>
<div class="block usep drugH1Div" id="F53570116"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of stable, symptomatic heart failure due to dilated cardiomyopathy in patients who are in sinus rhythm with increased heart rate (FDA approved in ages ≥6 months to &lt;18 years); to reduce the risk of hospitalization for worsening heart failure in patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤35% who are in sinus rhythm with resting heart rate ≥70 beats per minute (bpm) and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use (FDA approved in adults).</p></div>
<div class="block cyt drugH1Div" id="F28019062"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F28019059"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: May enhance the bradycardic effect of Ivabradine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Ivabradine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Ivabradine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Ivabradine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Ivabradine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Bradycardia-Causing Agents may enhance the arrhythmogenic effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Fingolimod.  Management: Consult with the prescriber of any bradycardia-causing agent to see if the agent could be switched to an agent that does not cause bradycardia prior to initiating fingolimod. If combined, perform continuous ECG monitoring after the first fingolimod dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit Juice: May increase the serum concentration of Ivabradine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the arrhythmogenic effect of Ivabradine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Ponesimod.  Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod.  Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May enhance the arrhythmogenic effect of Ivabradine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F27857555"><span class="drugH1">Food Interactions</span>
<p style="text-indent:-2em;margin-left:2em;">Food: Absorption delayed by 1 hour and AUC increased by 20% to 40% when taken with food. Management: Take with food to reduce variability in exposure.</p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit juice: Exposure increased twofold after ingestion of grapefruit juice. Management: Avoid consumption of grapefruit juice (Nawarskas 2015).</p></div>
<div class="block rep_considerations drugH1Div" id="F49307969"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Effective contraception is recommended in women of reproductive potential.</p></div>
<div class="block pri drugH1Div" id="F27857535"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events have been observed in animal reproduction studies, and fetal harm may occur if ivabradine is administered to pregnant women. If treatment is needed during pregnancy, closely monitor for destabilization of heart failure that could potentially result from heart rate slowing caused by ivabradine, especially during the first trimester. Pregnant women with chronic heart failure should also be monitored for preterm birth.</p></div>
<div class="block mopp drugH1Div" id="F53570115"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Heart rate (baseline, with dosage changes and as needed while on therapy); monitor heart rate more closely if receiving other negative chronotropes (eg, amiodarone, beta-blockers, digoxin); blood pressure; regularly monitor cardiac rhythm.</p></div>
<div class="block pha drugH1Div" id="F27857541"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Selective and specific inhibition of the hyperpolarization-activated cyclic nucleotide-gated (HCN) channels (f-channels) within the sinoatrial (SA) node of cardiac tissue resulting in disruption of <i>I</i>
<sub>f</sub> ion current flow prolonging diastolic depolarization, slowing firing in the SA node, and ultimately reducing heart rate. Has not demonstrated effects on myocardial contractility or relaxation, ventricular repolarization, or conduction apart from the sinus node effects. Partial inhibition of the retinal <i>I</i>
<sub>h</sub> current (similar to the cardiac <i>I</i>
<sub>f</sub> current) may explain visual disturbances (eg, phosphenes) (Nawarskas 2015).</p></div>
<div class="block phk drugH1Div" id="F27857542"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Pharmacokinetic data (drug exposure) in pediatric patients 6 months to &lt;18 years of age were observed to be similar to adults.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~100 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~70%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively intestinal and hepatic via CYP3A4; major active metabolite equipotent to ivabradine is the N-desmethylated derivative (S 18982) which is also metabolized by CYP3A4</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~40%; AUC increased 20% to 40% with food</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Distribution: 2 hours; Effective: ~6 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: ~1 hour (fasting); ~2 hours (with food)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces and urine (~4% as unchanged drug)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F28018875"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Ivabrad</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Procoralan</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ivabradin 1a pharm | Ivabradin aristo | Ivabradin genericon | Ivabradin hcs | Ivabradin ratiopharm | Ivabradin sandoz | Ivabradin stada | Ivabradine accord | Ivacorlan | Procoralan</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo ivabradine | Cobadine | Coralan</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Corabid | Delpino | Ivanor | Ivaprex | Ivaten</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Ivabradine accord | Ivabradine krka | Ivabradine sandoz | Procoralan</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Apredonav | Bixebra | Brediwal | Corledin | Ilibrift | Inevica | Ivabenor | Ivabradine accord | Ivabradine mylan | Raenom</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Ivahart | Procoralan</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Ivabradin mepha | Ivabradin mylan | Ivabradine sandoz | Procoralan</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Procoralan</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Corlentor</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Ivabeat | Ivabradina | Ivazyd | Procoralan</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Bixebra | Ivabradin sandoz | Ivabradin teva | Ivabradin zentiva | Ivabradine accord | Ivabradine aurovitas | Ivabradine auxilto | Ivabradine glenmark | Procoralan | Raenom</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ivabalan | Ivabradin | Ivabradin 1a pharm | Ivabradin abz | Ivabradin al | Ivabradin aristo | Ivabradin axiromed | Ivabradin beta | Ivabradin glenmark | Ivabradin Heumann | Ivabradin mylan | Ivabradin puren | Ivabradin ratiopharm | Ivabradin zentiva | Ivabradine accord | Ivabradine anpharm | Procoralan</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Procoralan</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Procoralan</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Bixebra | Brediwal | Ivabradine accord | Ivabradine grindeks | Ivabradine mylan | Procoralan</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Adwistadine | Angiobradine | Bradipect | Procoralan | Savapran</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Corlentor | Ivabradina alter | Ivabradina aurovitas | Ivabradina cinfa | Ivabradina combix | Ivabradina kern pharma | Ivabradina Krka | Ivabradina mylan | Ivabradina normon | Ivabradina pensa | Ivabradina qualigen | Ivabradina ratiopharm | Ivabradina sandoz | Ivabradina tarbis | Ivabradina tecnigen | Ivabradina tevagen | Ivabradina vir | Ivabradina viso farmaceutica | Procoralan</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Ivabradine accord | Procoralan</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Ivabradine accord | Ivabradine alter | Ivabradine arrow | Ivabradine biogaran | Ivabradine cristers | Ivabradine eg | Ivabradine krka | Ivabradine mylan | Ivabradine sandoz | Ivabradine teva sante | Ivabradine zentiva | Ivabradine zydus | Procoralan</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Ivabradine | Ivabradine chanelle medical | Ivabradine milpharm | Ivabradine zentiva | Procoralan</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Apredonav | Bravigo | Doborel | Ivabradine demo | Procoralan</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Coralan</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Corlentor</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Bravadin | Inevica | Ivabradin sandoz | Ivabradine anpharm | Procoralan | Raenom</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Coralan</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Ivabradine accord | Ivabradine krka | Ivabradine rowex | Procoralan</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Beat hf | Bradia | Bradiswift | Corabrad | Coralan | Coralan od | Ibdine | Inapure | Inapure er | Irban | Irban od | Ischevia | Ivabeat | Ivabeat od | Ivabid | Ivabid od | Ivables | Ivables od | Ivablock | Ivabrad | Ivabrad od | Ivabradin | Ivabratco | Ivabratco od | Ivadin xr | Ivalink od | Ivamac | Ivamac od | Ivaniche | Ivanode | Ivantra | Ivapace | Ivarest | Ivazine | Iverzac | Recard</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Ivabradina accord | Ivabradina aristo | Ivabradina aurobindo | Ivabradina doc generici | Ivabradina eg | Ivabradina Krka | Ivabradina sandoz | Ivabradina Teva Italia | Ivabradina zentiva</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Procoralan</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Coralan</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Bradin | Ivabeat | Ivadin | Procoralan</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Procoralan</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Procoralan</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Ivabradine arrow | Procoralan</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Apredonav | Bixebra | Brediwal | Corlentor | Ivabradine actavis | Ivabradine anpharm | Ivabradine grindeks | Ivabradine ingen pharma | Ivabradine mylan | Ivabradine zentiva | Procoralan</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Procoralan</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Apredonav | Bixebra | Brediwal | Brivecor | Corlentor | Ivabradine accord | Ivabradine actavis | Ivabradine grindeks | Ivabradine mylan | Ivabradine zentiva | Procoralan | Raenom</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Lancoryl | Procoralan | Vadrilev</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Coralan | Ivaswift</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Corlentor | Ivabradine 5mg teva | Ivabradine 7,5mg teva | Ivabradine accord | Ivabradine aurobindo | Ivabradine cf | Ivabradine glenmark | Ivabradine mylan | Ivabradine sandoz | Ivabradine xiromed | Procoralan</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Ivabradine accord | Procoralan</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Coralan</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Procoralan</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Ivabradine | Siftus</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Bradia | Bradin | Coradin | Coralan | Iva | Ivab | Ivabar | Ivabrad | Ivacard | Ivadin | Ivadine | Ivagen | Ivamed | Ivanode | Ivasaf | Ivaset | Ivatab | Ixsea | Mivab | Noracor | Rhytab | Sivab | Vabrasave | Vabri | Vabrin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Bixebra | Inevica | Ivab | Ivabradine accord | Ivabradine anpharm | Ivabradine aurovitas | Ivabradine genoptim | Ivabradine mylan | Ivabradine zentiva | Ivares | Ivohart | Raenom</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Corlanor</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Ivabradina accord | Ivabradina alter | Ivabradina aurovitas | Ivabradina bluepharma | Ivabradina ciclum | Ivabradina farmoz | Ivabradina kern pharma | Ivabradina Krka | Ivabradina Mecinam | Ivabradina mylan | Ivabradina ratiopharm | Ivabradina sandoz | Ivabradina teva | Ivabradina tolife | Ivabradina zentiva | Procoralan | Vascorlen</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Anginodil | Bradina | Ivabradina natrodale | Procoralan</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Procoralan</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Apredonav | Bixebra | Corlentor | Felocord | Ivabradina accord | Ivabradina aurobindo | Ivabradine zentiva | Procoralan | Raenom</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Bravadin | Coraxan | Ivabradine | Ivabradine canon | Raenom | Vivaroxan</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Procoralan</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Ivabradin krka | Ivabradin Medical Valley | Ivabradine accord | Ivabradine anpharm | Procoralan</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Coralan</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Bixebra | Brediwal | Inevica | Ivabradin mylan | Ivabradin stada | Procoralan</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Bixebra | Bradimed | Ivabradin sandoz | Ivabradin stada | Ivabradin teva | Ivabradine anpharm | Ivabradine glenmark | Ivabradine mylan | Ivabradine zentiva | Raenom</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Coralan</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Procoralan</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Coralan</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Coralan</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Bravadin | Coraxan | Ivakard | Raenom</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Procoralan</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Procoralan</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Nisten | Procoralan</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Coralan | Ivabradine unicorn | Ivangin | Ivolan | Pulsidon</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22927555">
<a name="22927555"></a>Borer JS, Böhm M, Ford I, et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. <i>Eur Heart J</i>. 2012;33(22):2813-2820.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivabradine-pediatric-drug-information/abstract-text/22927555/pubmed" id="22927555" target="_blank">22927555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12718562">
<a name="12718562"></a>Camm AJ, Lau CP. Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. <i>Drugs R D</i>. 2003;4(2):83-89.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivabradine-pediatric-drug-information/abstract-text/12718562/pubmed" id="12718562" target="_blank">12718562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22981555">
<a name="22981555"></a>Cappato R, Castelvecchio S, Ricci C, Bianco E, Vitali-Serdoz L, et al. Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation. <i>J Am Coll Cardiol</i>. 2012;60(15):1323-1329. doi: 10.1016/j.jacc.2012.06.031.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivabradine-pediatric-drug-information/abstract-text/22981555/pubmed" id="22981555" target="_blank">22981555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cice.1">
<a name="Cice.1"></a>Cice G, D'Lsaa S, D'Andrea A, et al. Elderly patients with heart failure and preserved ejection fraction: effects of ivabradine [abstract]. <i>Eur Heart J</i>. 2013;34(suppl 1). http://eurheartj.oxfordjournals.org/content/34/suppl_1/P3329
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25158669">
<a name="25158669"></a>Cocco G, Jerie P. Torsades de pointes induced by the concomitant use of ivabradine and azithromycin: an unexpected dangerous interaction. <i>Cardiovasc Toxicol</i>. 2015;15(1):104-106. doi: 10.1007/s12012-014-9274-y.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivabradine-pediatric-drug-information/abstract-text/25158669/pubmed" id="25158669" target="_blank">25158669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Corlanor.1">
<a name="Corlanor.1"></a>Corlanor (ivabradine) [prescribing information]. Thousand Oaks, CA: Amgen Inc; August 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Corlentor.2">
<a name="Corlentor.2"></a>Corlentor (ivabradine) [EPAR product information]. Wicklow, Ireland: Servier Industries, Ltd; April 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23182125">
<a name="23182125"></a>Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. <i>J Am Coll Cardiol</i>. 2012;60(24):e44-e164. doi:10.1016/j.jacc.2012.07.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivabradine-pediatric-drug-information/abstract-text/23182125/pubmed" id="23182125" target="_blank">23182125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18757088">
<a name="18757088"></a>Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. <i>Lancet</i>. 2008;372(9641):807-816.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivabradine-pediatric-drug-information/abstract-text/18757088/pubmed" id="18757088" target="_blank">18757088</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25176136">
<a name="25176136"></a>Fox K, Ford I, Steg PG, et al. Ivabradine in stable coronary artery disease without clinical heart failure. <i>N Engl J Med</i>. 2014;371(12):1091-1099. doi:10.1056/NEJMoa1406430<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivabradine-pediatric-drug-information/abstract-text/25176136/pubmed" id="25176136" target="_blank">25176136</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lancora.1">
<a name="Lancora.1"></a>Lancora (ivabradine) [product monograph]. Laval, Quebec, Canada: Servier Canada Inc; May 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33446410">
<a name="33446410"></a>Maddox TM, Januzzi JL Jr, Allen LA, et al; Writing Committee. 2021 update to the 2017 ACC Expert Consensus Decision Pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. <i>J Am Coll Cardiol.</i> 2021;77(6):772-810. doi:10.1016/j.jacc.2020.11.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivabradine-pediatric-drug-information/abstract-text/33446410/pubmed" id="33446410" target="_blank">33446410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25911606">
<a name="25911606"></a>Melgari D, Brack KE, Zhang C, et al. hERG Potassium Channel Blockade by the HCN Channel Inhibitor Bradycardic Agent Ivabradine. <i>J Am Heart Assoc</i>. 2015;4(4). pii: e001813. doi: 10.1161/JAHA.115.001813.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivabradine-pediatric-drug-information/abstract-text/25911606/pubmed" id="25911606" target="_blank">25911606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25438492">
<a name="25438492"></a>Mittal SR. Slow junctional rhythm, QTc prolongation and transient torsades de-pointes following combined use of Ivabradine, Diltiazem and Ranolazine. <i>J Assoc Physicians India</i>. 2014;62(5):426-427.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivabradine-pediatric-drug-information/abstract-text/25438492/pubmed" id="25438492" target="_blank">25438492</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23996286">
<a name="23996286"></a>Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. <i>Eur Heart J</i>. 2013;34(38):2949-3003. doi: 10.1093/eurheartj/eht296.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivabradine-pediatric-drug-information/abstract-text/23996286/pubmed" id="23996286" target="_blank">23996286</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19796572">
<a name="19796572"></a>Murat SN, Orcan S, Akdemir R, Dogan M, Kara E, Balci M. Arrhythmic effects of ivabradine in patients with coronary artery disease. <i>Clin Invest Med</i>. 2009;32(5):E322-E326.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivabradine-pediatric-drug-information/abstract-text/19796572/pubmed" id="19796572" target="_blank">19796572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2011">
<a name="NICE.2011"></a>National Institute for Health and Care Excellence. Management of stable angina (NICE clinical guideline 126). http://guidance.nice.org.uk/cg126. Published July 2011. Updated December 2012. Accessed June 3, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25839989">
<a name="25839989"></a>Nawarskas JJ, Bowman BN, Anderson JR. Ivabradine: A unique and intriguing medication for treating cardiovascular disease. <i>Cardiol Rev</i>. 2015; epub ahead of print.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivabradine-pediatric-drug-information/abstract-text/25839989/pubmed" id="25839989" target="_blank">25839989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26409259">
<a name="26409259"></a>Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>J Am Coll Cardiol</i>. 2015. pii: S0735-1097(15)05840-4. doi: 10.1016/j.jacc.2015.08.856.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivabradine-pediatric-drug-information/abstract-text/26409259/pubmed" id="26409259" target="_blank">26409259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23426376">
<a name="23426376"></a>Ptaszynski P, Kaczmarek K, Ruta J, Klingenheben T, Cygankiewicz I, et al. Ivabradine in combination with metoprolol succinate in the treatment of inappropriate sinus tachycardia. <i>J Cardiovasc Pharmacol Ther</i>. 2013;18(4):338-344.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivabradine-pediatric-drug-information/abstract-text/23426376/pubmed" id="23426376" target="_blank">23426376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20801500">
<a name="20801500"></a>Swedberg K, Komajda M, Böhm M, et al; SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. <i>Lancet</i>. 2010;376(9744):875-885. doi:10.1016/S0140-6736(10)61198-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivabradine-pediatric-drug-information/abstract-text/20801500/pubmed" id="20801500" target="_blank">20801500</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19136486">
<a name="19136486"></a>Tardif JC, Ponikowski P, Kahan T; ASSOCIATE Study Investigators. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. <i>Eur Heart J</i>. 2009;30(5):540-548. doi:10.1093/eurheartj/ehn571<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivabradine-pediatric-drug-information/abstract-text/19136486/pubmed" id="19136486" target="_blank">19136486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed January 5, 2024.</div>
</li></ol></div><div id="topicVersionRevision">Topic 121652 Version 80.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
